New Antimalarial Drug Development in India: Radical Curative Agents CIDRI 80/53 (Elubaquine) and WR 238605 (Tafenoquine)
IR@CDRI: CSIR-Central Drug Research Institute, Lucknow
View Archive Info| Field | Value | |
| Creator |
Dutta, G P
Puri, S K |
|
| Date |
2009-09-08T09:02:16Z
2009-09-08T09:02:16Z 2003 |
|
| Identifier |
Proc Indian National Science Academy -2003-B69 No.6 871-882
http://hdl.handle.net/123456789/507 |
|
| Description |
Global efforts had been continued for the last 50) years, to find a safe radical curative (anti-relapse) drug to replace primaquine for the treatment of Plasomodium vivax and P. ovale, Throughout the world, more than 250 potential tissue. schizontocides had been synthesized and screened, and two new primaquine derivatives had been identified in primate malaria radical curative tests which could be the candidate drugs to replace primaquine:
|
|
| Format |
6263850 bytes
application/pdf |
|
| Language |
en
|
|
| Subject |
Malaria
Anti-relapse drugs CDRI 80/53/Bulaquine/Elubagttine WR 238605/ Tafenoquine Antimalarials Plasmodium Gametocytocide Aablaquin |
|
| Title |
New Antimalarial Drug Development in India: Radical Curative Agents CIDRI 80/53 (Elubaquine) and WR 238605 (Tafenoquine)
|
|
| Type |
Article
|
|